Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT06157541




Registration number
NCT06157541
Ethics application status
Date submitted
26/11/2023
Date registered
6/12/2023
Date last updated
31/05/2024

Titles & IDs
Public title
T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma
Scientific title
Phase I/II Clinical Trial of Allogeneic Cytomegalovirus-specific T Cells in Combination With Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma Multiforme
Secondary ID [1] 0 0
P3894 / MSD-MK3475-E78
Universal Trial Number (UTN)
Trial acronym
TCaP
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Glioblastoma Multiforme 0 0
Astrocytoma, Grade IV 0 0
Condition category
Condition code
Cancer 0 0 0 0
Brain
Cancer 0 0 0 0
Children's - Brain

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - Allogeneic cytomegalovirus-specific T cells
Treatment: Drugs - Pembrolizumab

Experimental: Part 1 - Patients with recurrent disease. Interventions:
allogeneic CMV-specific T cells (cell suspension for infusion), dose cohorts: 2 × 10^7 cells, 4 × 10^7 cells, 8 × 10^7 cells; 4 infusions; administered weekly
pembrolizumab 400 mg (solution for injection); 18 infusions; administered every 6 weeks

Experimental: Part 2 Group A - Patients with recurrent disease. Interventions:
allogeneic CMV-specific T cells (cell suspension for infusion), maximum-tolerated dose identified in phase I; 4 infusions; administered weekly
pembrolizumab 400 mg (solution for injection); 18 infusions; administered every 6 weeks

Experimental: Part 2 Group B - Patients with newly diagnosed disease. Interventions:
allogeneic CMV-specific T cells (cell suspension for infusion), maximum-tolerated dose identified in phase I; 4 infusions; administered weekly
pembrolizumab 400 mg (solution for injection); 18 infusions; administered every 6 weeks


Other interventions: Allogeneic cytomegalovirus-specific T cells
Allogeneic cytomegalovirus (CMV)-specific T cells generated from the blood of healthy CMV-seropositive donors

Treatment: Drugs: Pembrolizumab
A humanised immunoglobulin G4 (IgG4) monoclonal antibody (mAb) specific for the programmed cell death 1 (PD-1) receptor
Intervention code [1] 0 0
Other interventions
Intervention code [2] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Incidence of dose-limiting toxicities
Timepoint [1] 0 0
Within 49 days of receiving the first dose of study drug
Primary outcome [2] 0 0
Incidence of adverse events and clinically significant changes in laboratory parameters, vital signs, and electrocardiograms (ECGs)
Timepoint [2] 0 0
Within 49 days of the first dose of study drug
Primary outcome [3] 0 0
Percentage of participants with confirmed complete response (CR) or partial response (PR)
Timepoint [3] 0 0
Within 25 months of the first dose of study drug
Primary outcome [4] 0 0
Percentage of participants with confirmed complete response (CR), partial response (PR), or stable disease (SD)
Timepoint [4] 0 0
Within 25 months of the first dose of study drug
Primary outcome [5] 0 0
Duration of response
Timepoint [5] 0 0
Within 25 months of the first dose of study drug
Primary outcome [6] 0 0
Overall survival (percentage of participants alive)
Timepoint [6] 0 0
6 months
Primary outcome [7] 0 0
Progression-free survival (percentage of participants with no evidence of further disease progression)
Timepoint [7] 0 0
6 months
Secondary outcome [1] 0 0
Percentage of participants with confirmed CR or PR
Timepoint [1] 0 0
Within 25 months of the first dose of study drug
Secondary outcome [2] 0 0
Percentage of participants with confirmed CR, PR, or SD
Timepoint [2] 0 0
Within 25 months of the first dose of study drug
Secondary outcome [3] 0 0
Duration of response
Timepoint [3] 0 0
Within 25 months of the first dose of study drug
Secondary outcome [4] 0 0
Overall survival (percentage of participants alive)
Timepoint [4] 0 0
6 months
Secondary outcome [5] 0 0
Progression-free survival (percentage of participants with no evidence of further disease progression)
Timepoint [5] 0 0
6 months
Secondary outcome [6] 0 0
Incidence of adverse events and clinically significant changes in laboratory parameters, vital signs, and ECGs
Timepoint [6] 0 0
Within 25 months of the first dose of study drug

Eligibility
Key inclusion criteria
1. At least 18 years of age on the day of signing informed consent, with histologically
confirmed diagnosis of GBM or astrocytoma Grade 4^.

a. For participants with recurrent GBM or astrocytoma grade 4, histological
confirmation of primary diagnosis is available i. First occurrence of disease
progression with radiological confirmation =12 weeks from completion of radiation
therapy.

ii. Where surgical resection of recurrent disease occurred, histological confirmation
of GBM or astrocytoma Grade 4 is required.

b. For participants with newly diagnosed GBM or astrocytoma Grade 4, histological
confirmation of diagnosis is required i. Participant, in consultation with their
treating clinicians, is willing to delay the commencement of standard of care adjuvant
temozolomide until the completion of CMV-specific T cell therapy infusions.

^Note: Histological confirmation using the 2016 or 2021 World Health Organization
(WHO) Classification of Tumours of the central nervous system (CNS) is acceptable and
classification edition will be noted.

2. Male participants: Must agree to use contraception during the treatment period and for
at least 180 days after the last dose of study treatment and refrain from donating
sperm during this period.

3. Female participants: Must not be pregnant or undergoing in vitro fertilisation or
breastfeeding, and at least one of the following conditions applies:

1. Not a woman of childbearing potential (WOCBP) OR

2. A WOCBP who agrees to follow contraceptive guidance during the treatment period
and for at 120 days after the last dose of study treatment.

4. Provision of written informed consent for the trial. Approved interpreters will be
used for patients who do not have sufficient understanding of English for informed
consent to be obtained without an interpreter.

5. Participants who have AEs due to previous anti-cancer therapies must have recovered to
=Grade 1 or baseline. Participants with endocrine-related AEs who are adequately
treated with hormone replacement or participants who have =Grade 2 neuropathy are
eligible. Participants with >Grade 1 adverse events (AEs) due to previous anti-cancer
therapies may be allowed to enrol on a case-by-case basis in discussion with the study
Sponsor, if it is determined that it will not put the participant at a higher risk of
study-related AEs or interfere with the integrity of the study outcome.

6. For participants with disease progression, this should be the first evidence of
measureable disease based on modified RANO criteria. Lesions situated in a previously
irradiated area are considered measurable if progression has been demonstrated in such
lesions.

7. CMV-positive serology

8. Provision of consent for the use of archival formalin-fixed, paraffin embedded or
fresh tumour tissue obtained at the time of surgical resection or excisional biopsy.

9. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
Evaluation of ECOG is to be performed within 7 days prior to the first dose of study
intervention.

10. Have a life expectancy of at least 6 months.

11. Have adequate organ function. Specimens must be collected within 10 days prior to the
start of study intervention.

12. Have availability of an human leukocyte antigen (HLA)-matched batch of allogeneic
CMV-specific T cells.

13. Provision of consent to access to Medicare Benefits Schedule (MBS) and Pharmaceutical
Benefits Scheme (PBS) patient/provider health information collected by Services
Australia (phase II participants only).

14. Criteria for known hepatitis B and C positive participants:

Hepatitis B and C screening tests are not required unless:

- Known history of hepatitis B virus (HBV) or hepatitis C virus (HCV) infection

- As mandated by local health authority

14.1 Hepatitis B-positive participants:

- Participants who are HBsAg positive are eligible if they have received HBV anti-viral
therapy for at least 4 weeks and have undetectable HBV viral load prior to enrolment.

- Participants should remain on anti-viral therapy throughout study intervention and
follow local guidelines for HBV anti-viral therapy post completion of study
intervention

14.2 Participants with history of HCV infection are eligible if HCV viral load is
undetectable at screening.

• Participants must have completed curative anti-viral therapy at least 4 weeks prior to
enrolment.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. A WOCBP who has a positive urine pregnancy test within 72 hours prior to the first
dose of study intervention (see Appendix 3). If the urine test is positive or cannot
be confirmed as negative, a serum pregnancy test will be required.

2. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with
an agent directed to another stimulatory or co-inhibitory T-cell receptor.

3. Has received prior systemic anti-cancer therapy or investigational agents within 4
weeks prior to study intervention, with the exception of temozolomide, which is
permitted during the trial.

4. Recurrent disease cohorts only: Has not yet recovered from all radiation-related
toxicities not requiring corticosteroids other than dexamethasone, or has had
radiation pneumonitis.

Note: A 1-week washout is permitted for palliative radiation of non-CNS disease (=2
weeks of radiotherapy). Participants receiving dexamethasone must be clinically stable
and receiving a stable or weaning dose of =2 mg/day 1-2 weeks prior to the
commencement of pembrolizumab.

5. Has received a live vaccine or live-attenuated vaccine within 30 days prior to the
first dose of study intervention. Administration of killed vaccines is allowed.

6. Has received in an investigational agent, or has used an investigational device within
4 weeks prior to the first dose of study intervention.

7. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
(in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of
immunosuppressive therapy within 7 days prior to the first dose of study drug.

8. Known additional malignancy that is progressing or has required active treatment
within the past 5 years.

Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of
the skin, prostate cancer treated with radical prostatectomy, or carcinoma in situ,
excluding carcinoma in situ of the bladder, who have undergone potentially curative
therapy are not excluded. Participants with additional malignancy within the past 5
years may be allowed to enrol on a case-by-case basis, in discussion with the study
Sponsor, if the malignancy is deemed of very low recurrence potential and the
participant has completed curative intent therapy.

9. Has a previous known GBM/astrocytoma grade 4 recurrence previously treated with
surgery, radiotherapy and/or chemotherapy, and evidence of further progression or
recurrence.

10. Has severe hypersensitivity (=Grade 3) to pembrolizumab and/or any of its excipients.

11. Has active autoimmune disease that has required systemic treatment in the past 2 years
except replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid).

12. Has a history of (non-infectious) pneumonitis/interstitial lung disease that required
steroids or has current pneumonitis/interstitial lung disease.

13. Has an active infection requiring systemic therapy.

14. Has a known history of human immunodeficiency virus (HIV) infection. Note: No HIV
testing is required unless mandated by a local health authority.

15. Concurrent active hepatitis B (defined as HBsAg positive and/or detectable HBV DNA)
and hepatitis C virus (defined as anti-HCV Ab positive and detectable HCV RNA)
infection.

Note: Hepatitis B and C screening tests are not required unless:

- Known history of HBV and HCV infection

- As mandated by local health authority

16. Has not adequately recovered from major surgery or has ongoing surgical complications.

17. Has a history or current evidence of any condition, therapy, or laboratory abnormality
or other circumstance that might confound the results of the study, interfere with the
participant's participation for the full duration of the study, such that it is not in
the best interest of the participant to participate, in the opinion of the treating
investigator.

18. Has known psychiatric or substance-abuse disorders that would interfere with
cooperation with the requirements of the trial.

19. Is pregnant or breastfeeding or expecting to conceive or father children within the
projected duration of the study, starting with the screening visit through 120 days
after the last dose of trial treatment.

20. Has had an allogeneic tissue/solid organ transplant or stem cell transplant.

21. Has a baseline corrected QT interval (QTc) of >450 ms, assessed by ECG. If the
participant's screening ECG records a QTc of >450 ms, the ECG is to be done in
triplicate and the average of the QTc is to be recorded. If the QTc remains >450 ms,
the participant will be excluded from enrolment.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
Phase
Phase 1/Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
8/02/2024
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/01/2028
Actual
Sample size
Target
58
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD,VIC
Recruitment hospital [1] 0 0
Newro Foundation - Bowen Hills
Recruitment hospital [2] 0 0
Royal Brisbane and Women's Hospital - Herston
Recruitment hospital [3] 0 0
Princess Alexandra Hospital - Woolloongabba
Recruitment hospital [4] 0 0
Austin Hospital - Heidelberg
Recruitment postcode(s) [1] 0 0
4006 - Bowen Hills
Recruitment postcode(s) [2] 0 0
4006 - Herston
Recruitment postcode(s) [3] 0 0
4102 - Woolloongabba
Recruitment postcode(s) [4] 0 0
3084 - Heidelberg

Funding & Sponsors
Primary sponsor type
Other
Name
Queensland Institute of Medical Research
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
CUREator
Address [1] 0 0
Country [1] 0 0
Other collaborator category [2] 0 0
Commercial sector/Industry
Name [2] 0 0
Merck Sharp & Dohme LLC
Address [2] 0 0
Country [2] 0 0
Other collaborator category [3] 0 0
Other
Name [3] 0 0
The Newro Foundation
Address [3] 0 0
Country [3] 0 0
Other collaborator category [4] 0 0
Other
Name [4] 0 0
Royal Brisbane and Women's Hospital
Address [4] 0 0
Country [4] 0 0
Other collaborator category [5] 0 0
Other
Name [5] 0 0
Princess Alexandra Hospital, Brisbane, Australia
Address [5] 0 0
Country [5] 0 0
Other collaborator category [6] 0 0
Other
Name [6] 0 0
Austin Hospital, Melbourne Australia
Address [6] 0 0
Country [6] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The goal of this clinical trial is to test a combined therapy approach (allogeneic
cytomegalovirus [CMV]-specific T cells and pembrolizumab) in patients with brain cancer. The
type of brain cancer being studied is glioblastoma multiforme/astrocytoma grade 4.

The purpose of part 1 of this study is to determine the maximum-tolerated dose and/or
recommended dose(s) for future exploration of allogeneic CMV-specific T cells as monotherapy
or in combination with pembrolizumab in patients with recurrent GBM/astrocytoma grade 4. Part
2 of the study aims to investigate the anti-tumour activity of allogeneic CMV-specific T
cells as monotherapy or in combination with pembrolizumab, assessed by magnetic resonance
imaging and survival, in patients with recurrent or newly diagnosed GBM/grade 4 astrocytoma.
Trial website
https://clinicaltrials.gov/ct2/show/NCT06157541
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Rajiv Khanna, PhD
Address 0 0
QIMR Berghofer Medical Research Institute
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Michelle Neller, PhD
Address 0 0
Country 0 0
Phone 0 0
+61 7 3362 0412
Fax 0 0
Email 0 0
immunotherapy@qimrberghofer.edu.au
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT06157541